Literature DB >> 28346238

Management of hypertension in 2017: targets and therapies.

Monica Ahluwalia1, Sripal Bangalore.   

Abstract

PURPOSE OF REVIEW: Approximately one-fourth of the adult population is diagnosed with hypertension, which has been associated with increased cardiovascular morbidity and mortality including cardiovascular death, myocardial infarction, heart failure and stroke. Early detection and treatment is key and can lead to a significant reduction in cardiovascular morbidity and mortality. RECENT
FINDINGS: In this review, we discuss the management and treatment strategies in patients with hypertension in the current era. Blood pressure (BP) targets will be reviewed in accordance with the recent literature and current guidelines. There is a controversy about lower BP target in patients with coronary artery disease with some studies showing a J-curve relationship but a recent randomized trial (SPRINT) showing a benefit, albeit with controversy as to how BP was measured in the trial. Nevertheless, lower BP targets come with a price of needing more medication (thus impacting cost and compliance) and increases in medication-related adverse effects. There is a growing recognition that angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, calcium antagonists or thiazide diuretics can be used a first-line therapy for hypertension. Evidence also supports the use of combination drug therapy as opposed to monotherapy for more synergistic effect on lowering of BP, offsetting side effects and for improved adherence to a drug regimen.
SUMMARY: Overall, we aim to review BP targets and medical therapies for hypertension in the current era, recognizing varying clinical characteristics such as comorbidities and patient-risk profile.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28346238     DOI: 10.1097/HCO.0000000000000408

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  7 in total

Review 1.  Extracellular Vesicle-Mediated Vascular Cell Communications in Hypertension: Mechanism Insights and Therapeutic Potential of ncRNAs.

Authors:  Ji-Ru Zhang; Hai-Jian Sun
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-22       Impact factor: 3.727

Review 2.  Preoperative Hypertension.

Authors:  Simon James Howell
Journal:  Curr Anesthesiol Rep       Date:  2018-02-08

3.  Ellisras Longitudinal Study 2017: association of hypertension with increasing levels of adiposity in 10- to 14-year-old boys and girls in the Eastern Cape (ELS 31).

Authors:  A Chungag; C M Tata; C R Sewani-Rusike; W Nel; B N Nkeh-Chungag
Journal:  Cardiovasc J Afr       Date:  2019 Sep/Oct       Impact factor: 1.167

4.  Screening of Angiotensin-I Converting Enzyme Inhibitory Peptides Derived from Caulerpa lentillifera.

Authors:  Cesarea Hulda Joel; Christoper C Y Sutopo; Arief Prajitno; Jui-Hsin Su; Jue-Liang Hsu
Journal:  Molecules       Date:  2018-11-16       Impact factor: 4.411

5.  Effects of Angiotensin-Converting Enzyme Inhibitors on Arterial Stiffness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Xiuli Li; Peng Chang; Qiongying Wang; Hao Hu; Feng Bai; Ningyin Li; Jing Yu
Journal:  Cardiovasc Ther       Date:  2020-02-25       Impact factor: 3.023

6.  Baicalin Protects Against Hypertension-Associated Intestinal Barrier Impairment in Part Through Enhanced Microbial Production of Short-Chain Fatty Acids.

Authors:  Dandan Wu; Liliqiang Ding; Xiaoting Tang; Wenjian Wang; Yu Chen; Teng Zhang
Journal:  Front Pharmacol       Date:  2019-10-28       Impact factor: 5.810

Review 7.  Adipokines and Arterial Stiffness in Obesity.

Authors:  Ioana Para; Adriana Albu; Mihai D Porojan
Journal:  Medicina (Kaunas)       Date:  2021-06-25       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.